Mar 04, 2021 / 05:50PM GMT
Yaron Benjamin Werber - Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Good afternoon, everybody, and thank you once again for the final day of the 41st Annual Cowen Healthcare Conference. I'm Yaron Werber from the biotech team. And it's a pleasure to moderate the fireside chat with Amgen, with my colleague, Gabe Schneider. And we are very pleased to have the full team here today. We have Peter Griffith, who's EVP and CFO; Murdo Gordon, EVP, Global Commercial Ops; and David Reese, EVP of R&D; and Arvind Sood, of course, our VP of Investor Relations.
Gentlemen, thank you so much for joining us. We appreciate it. And we have a box open on the screen. If anybody has questions, you can pop them in there and we'll do our best to ask them on your behalf or you can e-mail us directly, and we'll be happy to take them.
So Peter, maybe let me turn it over to you maybe for some introductory remarks about how the business is going, and then we'll dive into Q&A.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Amgen Inc at Cowen Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot